Dr Waleed Mohammed Consultant oncologist

Background

Dr Mohammed initially trained as a bio-scientist, specializing in genetics at the University of Cambridge and completing an MSc in biology at the University of Oxford, before delving into the pharmaceutical industry (Oxford Science Park and MRC Prion Unit at Queen Square, University College London).

He subsequently re-trained as a medic (Cambridge Graduate Course in Medicine), specializing in clinical oncology, undertaking specialist registrar training at Imperial College NHS Trust, The Royal Marsden Hospital and The Royal Sussex County Hospital. He has been a consultant clinical oncologist at Charing Cross Hospital since 2020, where he introduced, developed and established the SABR radiotherapy service.

He is a member of The Royal College of Physicians (London) and a Fellow of The Royal College of Radiologists (New Fellows Speaker award).

 

Expertise

Primary and secondary thoracic cancers (NSCLC, SCLC, LCNET, mesothelioma and thymic cancers); primary and secondary CNS (brain and spine) cancers (LGG, HGG, meningioma, ependymoma, medulloblastoma, pituitary tumours, pineal tumours and intra-cranial germ cell tumours); Cytotoxic Systemic Anti-Cancer Therapy (SACT), Immunotherapy/Check-Point Inhibitors (IO/CPI), Oral Tyrosine Kinase Inhibitors (TKI); Linac-based palliative/radical External Beam Radiotherapy (EBRT), Linac-based Stereo-tactic Ablative Radiotherapy (SABR), MR-Linac (MRL) SABR, Linac-based Stereotactic Radiosurgery (SRS), Gamma Knife based SRS (including frame-fitting) and Optune Tumour Treating Fields (TTF).

Research & publications

Early in his career as a geneticist, Dr Mohammed was involved in research elucidating the role of newly discovered genes in development of the early mouse embryo. He was also focused on investigating the biology of lysosomal storage disorders and prion disease in order to develop drug therapy.

As an oncology trainee, he investigated the short-term toxicity of brachytherapy in prostate cancer patients with inflammatory bowel disease, and was awarded first prize for best presentation at international conference level.

As a consultant, he is sub-investigator on a number of clinical trials, and has been focused on service development within the oncology department at Charing Cross Hospital, and most recently established and leads the new SABR radiotherapy service.

***

PKorolewicz JA, Scheiner B, Fulgenzi CAM, D'Alessio A, Cortellini A, Pascual C, Mehan A, Partridge S, Gujral DM, Mohammed W, Mohammed O, Grzesiak A, Booker L, Cleator S, Pokrovska T, Saleem W, Rackie J, Needham Y, Krell J, McNeish I, Tookman L, Park WE, Asif M, Evans JS, Pinato DJ. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden. Chemotherapy. 2024 Apr 27:1-7. doi: 10.1159/000539109. Epub ahead of print. PMID: 38679017

Hamish Sinclair, Kerlann Le Calvez, Jiarong Chen, Lillie Pakzad-Shahabi, Luke Dixon, Waleed Mohammed, Waqar Saleem, Matthew Williams, Estimating population-based incidence of brain metastases – a comprehensive incident cohort study, Neuro-Oncology, Volume 23, Issue Supplement_4, October 2021, Page iv21, https://doi.org/10.1093/neuonc/noab195.053


Seema Dadhania, Lillie Pakzad-Shahabi, Kerlann Le Calvez, Waqar Saleem, James Wang, Waleed Mohammed, Sanjay Mistry, Matthew Williams, BrainWear: Longitudinal, objective assessment of physical activity in 42 High Grade Glioma (HGG) patients, Neuro-Oncology, Volume 23, Issue Supplement_4, October 2021, Page iv3, https://doi.org/10.1093/neuonc/noab195.006


Mohammed W, Hoskin P, Henry A, Gomez-Iturriaga A, Robinson A, Nikapota A. Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease. Clin Oncol (R Coll Radiol). 2018 Sep;30(9):534-538. doi: 10.1016/j.clon.2018.06.007. Epub 2018 Jun 30. PMID: 30099986

Private practice

Visit the Imperial College Healthcare Private care website